Immunovant Inc expected to post a loss of 72 cents a share - Earnings Preview

Immunovant

28/05/2025 13:33

Immunovant Inc IMVT.OQ IMVT.O is expected to show no change in quarterly revenue when it reports  results on May 30 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Immunovant Inc is for a loss of 72 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Immunovant Inc is $51.00​, above​ its last closing price of $14.29. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.77
-0.75
-0.76
Missed
-1.4
Sep. 30 2024
-0.61
-0.60
-0.74
Missed
-23.9
Jun. 30 2024
-0.53
-0.53
-0.60
Missed
-13.8​
Mar. 31 2024
-0.41
-0.43
-0.52
Missed
-21.9
​​Dec. 31 2023
-0.44
-0.43
-0.36
Beat
16.5
Sep. 30 2023
-0.50
-0.47
-0.45
Beat
4.4​
Jun. 30 2023
-0.47
-0.45
-0.57
Missed
-27.7
Mar. 31 2023
-0.45
-0.43
-0.46
Missed
-7.5

This summary was machine generated May 28 at 12:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)